Director at BioMarin (NASDAQ: BMRN) awarded 7,490 RSUs

Rhea-AI Filing Summary

HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.

BIOMARIN PHARMACEUTICAL INC director Robert J. Hombach received a new equity award in the form of restricted stock units. On June 2, 2026, he was granted 7,490 shares of Common Stock as a compensation award, with no purchase price applicable to the grant.

Following this award, Hombach directly holds 49,360 shares of BioMarin common stock. This is a non-market transaction classified as a grant or award, rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HOMBACH ROBERT J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	--

Holdings After Transaction: Common Stock — 49,360 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 7,490 shares Holdings after grant: 49,360 shares Grant price per share: $0.00 per share +1 more

4 metrics

RSU grant size 7,490 shares Restricted stock units granted June 2, 2026

Holdings after grant 49,360 shares Total BioMarin common shares directly held after transaction

Grant price per share $0.00 per share Compensation grant, price not applicable

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

Restricted stock units, Common Stock, Grant, award, or other acquisition, direct ownership

4 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026. Price not applicable."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Common Stock financial

"security_title: "Common Stock" in the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

direct ownership financial

"ownership_type: "direct" indicating direct holdings by the reporting person"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/04/2026 - 06:09 PM Accepted by SEC EDGAR 06/04/2026 - 06:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMBACH ROBERT J.

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		7,490	A	$0(1)	49,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What stock award did BioMarin (BMRN) director Robert J. Hombach receive?

Robert J. Hombach received 7,490 restricted stock units of BioMarin common stock as a compensation grant. The award was made on June 2, 2026, and no purchase price applied to these shares.

Was Robert J. Hombach’s BioMarin (BMRN) award an open-market stock purchase?

No, the 7,490 BioMarin shares were granted as restricted stock units, not bought in the open market. The transaction code classifies it as a grant or award acquisition with a price per share of zero.

How many BioMarin (BMRN) shares does Robert J. Hombach now hold?

After the June 2, 2026 award, Robert J. Hombach directly holds 49,360 shares of BioMarin common stock. This total includes the newly granted 7,490 restricted stock units reported in the transaction.

What does the zero price per share mean for the BioMarin (BMRN) RSU grant?

The zero price per share indicates the 7,490 shares were granted as compensation, not purchased. Restricted stock units typically vest over time and do not require the director to pay a purchase price when awarded.

How is Robert J. Hombach’s BioMarin (BMRN) transaction classified?

The transaction is classified as an acquisition through a grant or award of common stock. It uses transaction code A, indicating a grant, award, or other acquisition of 7,490 restricted stock units on June 2, 2026.